JPMorgan Raises Illumina's Price Target to $130, Maintains Neutral Rating
Dec 16, 2025 14:50
CST Updated
14:50
Illumina
Diagnostic Product Developer
Gelonghui December 16 | JPMorgan raised Illumina's target price from $105 to $130 and maintained a "neutral" rating. (Gelonghui)